chaostrader Posted - 2 weeks ago

$NYXH Part of the loan agreement, Nyxoah will grant the EIB 468,384 synthetic warrants with a strike price of €8.11. These warrants are exercisable after five years or in exceptional situations, allowing the EIB to receive cash based on Nyxoah's stock performance​. https://www.pharmiweb.com/press-release/2024-07-03/nyxoah-has-signed-a-375-million-loan-facility-agreement-with-the-european-investment-bank

Moondusterke2 Posted - 2 weeks ago

$NYXH **

OpenOutcrier Posted - 3 weeks ago

$NYXH (+2.1% pre) Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank https://ooc.bz/l/36861

Stock_Titan Posted - 3 weeks ago

$NYXH Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank https://www.stocktitan.net/news/NYXH/nyxoah-has-signed-a-eu37-5-million-loan-facility-agreement-with-the-zy8nmuhtx7uk.html

Stock_Titan Posted - 3 weeks ago

$NYXH Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA https://www.stocktitan.net/news/NYXH/nyxoah-submits-fourth-and-final-module-in-pma-application-for-genio-s97mfyfzhrnu.html

AnaChart Posted - 1 month ago

$NYXH https://anachart.com/wp-content/uploads/ana_temp/1719234125_soc-img.jpg

DonCorleone77 Posted - 1 month ago

$INSP $NYXH $LLY Inspire Medical price target lowered to $170 from $210 at Stifel Stifel analyst Jonathan Block lowered the firm's price target on Inspire Medical (INSP) to $170 from $210 and keeps a Hold rating on the shares. Additional data from Eli Lilly's (LLY) SURMOUNT-OSA trial that was released late Friday afternoon raises more questions for Inspire Medical and the HGNS market than it offers answers, the analyst tells investors. The incremental information, notably the percent of obstructive sleep apnea, or OSA, patients no longer considered moderate or severe at week 52, makes the firm "more concerned on out-year numbers," and it lowered estimates and targets for both Inspire and Nyxoah (NYXH), the analyst added.

Americanbulls Posted - 1 month ago

$NYXH apparently the bear pattern is not confirmed. Prices continue to rise. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=NYXH

Stock_Titan Posted - 1 month ago

$NYXH Publication relating to transparency notifications https://www.stocktitan.net/news/NYXH/publication-relating-to-transparency-peo6f27ubcdn.html

TheDizPlinTrader Posted - 2 months ago

$NYXH slightly below where it should be, but a green finish is promising! I will come back and asses the situation with new levels soon. Have a lovely weekend! David.

Celz Posted - 2 months ago

$NYXH

TheDizPlinTrader Posted - 2 months ago

$NYXH Daily Analysis: 1-Hour Support & Resistance Zones 🚀 Current Price: $8.64 🔹 Support Levels: Immediate support at $8.65 (Just broke) Stronger support at $8.50 🔸 Resistance Levels: Immediate resistance at $8.90 Longer-term resistance at $9.05 📊 Watch these key levels for potential trading opportunities! Stay disciplined! ⚔️

DonCorleone77 Posted - 2 months ago

$NYXH Nyxoah 5.374M share Spot Secondary priced at $9.25 Cantor Fitzgerald acted as lead book running manager for the offering.

Stock_Titan Posted - 2 months ago

$NYXH Nyxoah Announces Pricing of Offering https://www.stocktitan.net/news/NYXH/nyxoah-announces-pricing-of-ybisb9v9zp4a.html

OpenOutcrier Posted - 2 months ago

$NYXH (-9.1% pre) Nyxoah Announces Proposed Offering of Ordinary Shares - GN https://ooc.bz/l/33802

DonCorleone77 Posted - 2 months ago

$NYXH Nyxoah files ordinary shares offering, no amount given Nyxoah announced the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. All of the ordinary shares are being offered by Nyxoah and there are no selling stockholders in the proposed offering. Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Degroof Petercam is acting as a co-manager.

Stock_Titan Posted - 2 months ago

$NYXH Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program https://www.stocktitan.net/news/NYXH/nyxoah-announces-reduction-of-the-maximum-amount-available-under-its-uvr3fvsw19fi.html

Stock_Titan Posted - 2 months ago

$NYXH Nyxoah Announces Proposed Offering of Ordinary Shares https://www.stocktitan.net/news/NYXH/nyxoah-announces-proposed-offering-of-ordinary-p89jqe3st439.html

Thestocktraderhubzee Posted - 2 months ago

$NYXH Oppenheimer Maintains Outperform on Nyxoah, Lowers Price Target to $15

Thestocktraderhubzee Posted - 2 months ago

$NYXH Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $17

Stock_Titan Posted - 2 months ago

$NYXH Nyxoah Reports First Quarter 2024 Financial and Operating Results https://www.stocktitan.net/news/NYXH/nyxoah-reports-first-quarter-2024-financial-and-operating-rqlwodj9iga6.html

Stock_Titan Posted - 2 months ago

$NYXH Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 https://www.stocktitan.net/news/NYXH/nyxoah-to-release-first-quarter-2024-financial-results-on-may-14-xpkxe7054h2e.html

TickerDD_com Posted - 3 months ago

From 3/5/2024, looking back across 22 Month-Ends for NYXH, Percentage Change of Average Monthly Price had More Negatives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $NYXH #NYXH #NYXHStock #TickerDD https://www.youtube.com/watch?v=UDFKwAgLjto

Stock_Titan Posted - 03/29/24

$NYXH Information on the total number of voting rights and shares https://www.stocktitan.net/news/NYXH/information-on-the-total-number-of-voting-rights-and-l8xrpi7rsvmw.html

Stock_Titan Posted - 4 months ago

$NYXH Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation https://www.stocktitan.net/news/NYXH/nyxoah-advances-patient-access-strategy-through-partnership-with-the-bpuhrtmpmk18.html

_StockTrader Posted - 4 months ago

Real-Time Stock Data $NYXH Price: 15.64 Volume: 33873 Market Cap: 536291936 PE Ratio: -8.182796 Powered by: AITX

AnaChart Posted - 4 months ago

$NYXH https://anachart.com/wp-content/uploads/ana_temp/1710939703_soc-img.jpg

DonCorleone77 Posted - 4 months ago

$NYXH 2 of 2 - Nyxoah announces DREAM study meets primary endpoints ....Study participants entered the DREAM study with a mean AHI of 28.0, mean ODI of 27.0 and mean body mass index of 28.5. At 12 months, 73 subjects were determined to be AHI responders, per the Sher criteria, resulting in an ITT AHI responder rate of 63.5%, and 82 subjects were determined to be ODI responders, resulting in an ODI responder rate of 71.3%. Subjects demonstrated a median 12-month AHI reduction of 70.8%, with similar AHI improvements in supine and non-supine sleeping positions. The safety results for the investigational treatment were favorable, with 11 serious adverse events, or SAEs, in ten subjects resulting in an SAE rate of 8.7%. Out of the 11 SAEs, three were device related and there were three explants.

DonCorleone77 Posted - 4 months ago

$NYXH 1 of 2 - Nyxoah announces DREAM study meets primary endpoints Nyxoah announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis. The DREAM study is a trial, being conducted under an investigational device exemption and is designed to support the marketing authorization of the Genio hypoglossal nerve stimulation system, or HGNS, in the United States. This multicenter, prospective, open-label, interventional study enrolled 115 patients and has co-primary efficacy endpoints of the Apnea-Hypopnea Index, or AHI, responder rate, per the Sher criteria, and the Oxygen Desaturation Index, or ODI, responder rate, both measured at 12 months. Subjects also were required to sleep supine for at least 60 minutes at their 12-month polysomnography test, or PSG....

Stock_Titan Posted - 4 months ago

$NYXH Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints https://www.stocktitan.net/news/NYXH/nyxoah-announces-dream-u-s-pivotal-study-meets-primary-0lpft5b0m7vw.html